APA (7th ed.) Citation

Fulgenzi, C. A. M., Dalla Pria, A., Leone, A. G., Martinez, M., Del Peral, E. F. M., Flores, M. E., . . . Pinato, D. J. (2025). STARKAP Protocol: Preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi's Sarcoma. BMC Cancer, 25(1), 1. https://doi.org/10.1186/s12885-025-14326-2

Chicago Style (17th ed.) Citation

Fulgenzi, Claudia A. M., Alessia Dalla Pria, Alberto Giovanni Leone, Maria Martinez, Elena Ferrer Martinez Del Peral, Maria Eleanor Flores, Mark Bower, and David J. Pinato. "STARKAP Protocol: Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART)-refractory HIV Associated Kaposi's Sarcoma." BMC Cancer 25, no. 1 (2025): 1. https://doi.org/10.1186/s12885-025-14326-2.

MLA (9th ed.) Citation

Fulgenzi, Claudia A. M., et al. "STARKAP Protocol: Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART)-refractory HIV Associated Kaposi's Sarcoma." BMC Cancer, vol. 25, no. 1, 2025, p. 1, https://doi.org/10.1186/s12885-025-14326-2.